



PRESS RELEASE

innate pharma®

Innate Pharma obtains ISO9001:2000 certification for its research and development activities in the field of immunotherapy

Marseille, September 2nd, 2005

Leader in innate immunity, Innate Pharma is a French biotechnology company focused on cancer immunotherapy. The company announced today its ISO9001:2000 certification for its research and development activities in the field of immunotherapy.

This certification marks a new milestone in the maturation of the company, obtained at a time when Innate Pharma is significantly building up its team, enlarging its portfolio of compounds and working on various new industrial partnerships.

"The ISO9001:2000 certification is unquestionably an important maturation step for Innate Pharma" said Hervé Brailly, CEO; "It is a key consideration when discussing industrial and commercial agreements with the pharmaceutical industry".

Mr. Jacques Beslin, Managing Director of the French certification body AFAQ AFNOR, said: *"European companies having sought and obtained this certification are few and far between, so Innate Pharma has every right to be proud of this success which confirms the company's global dimension and demonstrates its capacity to work according to quality standards as defined by the norm."*